How Orforglipron Stacks Up Against Wegovy and Zepbound Wegovy (semaglutide 2.4 mg weekly) produced an average weight loss of 14.9% over 68 weeks in the STEP 1 trial
This process helps reduce the intake of calories, thereby aiding in weight loss
"Tirzepatide: A New Frontier in Diabetes and Obesity Management." Endocrine Reviews, 44(2), 300-325
When prescribed and monitored by trained healthcare professionals, like those here at Yorktown Health, semaglutide and tirzepatide are considered safe and effective
For most GLP-1 medications, alopecia is not listed as a common adverse effect in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA)
In case of pre-existing heart disease, consult a healthcare professional